Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refrac...
Janus Kinase (JAK) inhibitors are the ones that inhibit the functional activity of enzymes that belong to Janus Kinase family such as JAK1, JAK2, JAK3 and TYK2 by interfering in the JAK-S...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Advances in genetics research have sparked a surge in interest in gene therapy in derma...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
